Genomics Growth
Search documents
Tempus AI signals sustained 25% genomics growth target through 2028 while achieving first positive adjusted EBITDA (NASDAQ:TEM)
Seeking Alpha· 2025-11-05 00:07
Group 1 - The article does not provide any specific content or key points related to a company or industry [1]
